Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- SEMIANNUAL BUSINESS RESULTS -2-
November 28, 2005
- Equal Partnership Needed between Investigators, Monitors and the CRC: JCROA Symposium
November 28, 2005
- SEMIANNUAL BUSINESS RESULTS
November 28, 2005
- SEMINAR
November 28, 2005
- Importance of Overseas Business Increases for Major Domestic Companies
November 28, 2005
- SURVEY 2 articles
November 28, 2005
- 13 Leading Pharma Companies Report 3.5% Growth in Sales: JPMA
November 28, 2005
- MEDICAL DEVICE NEWS IN BRIEF
November 28, 2005
- CROs Aim at Becoming Real Partners of Drug Firms: JCROA Chairman Mr Nakamura
November 28, 2005
- Industry, Doctors, Patients, Gov't Exchange Opinions on Drugs
November 28, 2005
- R&D NEWS IN BRIEF
November 28, 2005
- AHA's Scientific Sessions 2005
November 28, 2005
- MOF Proposes to Exclude "Non-prescription Drugs" from Insurance Coverage: Mr Mugitani
November 21, 2005
- BUSINESS NEWS IN BRIEF
November 21, 2005
- IMS Health Predicts 6-7% Growth in Global Drug Market in 2006
November 21, 2005
- Worldwide Sales of Olmesartan to Top \100 Bil. in 2006: Daiichi Sankyo
November 21, 2005
- Ono: Opalmon Tab, Long Allergy Season Boosts Sales 4.9%
November 21, 2005
- Astellas Seminar on Atopic Dermatitis
November 21, 2005
- Taisho: Slump of Self-medication Business Hurts Results
November 21, 2005
- REGULATORY NEWS IN BRIEF
November 21, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…